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ABSTRACT: Genes that alter disease risk only in combination with certain environmental exposures may not be detected
in genetic association analysis. By using methods accounting for gene-environment (G × E) interaction, we aimed to identify
novel genetic loci associated with breast cancer risk. Up to 34,475 cases and 34,786 controls of European ancestry from up
to 23 studies in the Breast Cancer Association Consortium were included. Overall, 71,527 single nucleotide polymorphisms
(SNPs), enriched for association with breast cancer, were tested for interaction with 10 environmental risk factors using
three recently proposed hybrid methods and a joint test of association and interaction. Analyses were adjusted for age, study,
population stratification, and confounding factors as applicable. Three SNPs in two independent loci showed statistically sig-
nificant association: SNPs rs10483028 and rs2242714 in perfect linkage disequilibrium on chromosome 21 and rs12197388
in ARID1B on chromosome 6. While rs12197388 was identified using the joint test with parity and with age at menarche
(P-values = 3 × 10−07), the variants on chromosome 21 q22.12, which showed interaction with adult body mass index (BMI)
in 8,891 postmenopausal women, were identified by all methods applied. SNP rs10483028 was associated with breast cancer
in women with a BMI below 25 kg/m2 (OR = 1.26, 95% CI 1.15–1.38) but not in women with a BMI of 30 kg/m2 or higher
(OR = 0.89, 95% CI 0.72–1.11, P for interaction = 3.2 × 10−05). Our findings confirm comparable power of the recent
methods for detecting G × E interaction and the utility of using G × E interaction analyses to identify new susceptibility loci.
Genet Epidemiol 38:84–93, 2014. Published 2013 Wiley Periodicals, Inc.∗
KEY WORDS: breast cancer risk; gene-environment interaction; polymorphisms; body mass index; case-control study
Introduction
The risk of breast cancer, the most common malignant dis-
ease in women, is known to be influenced by multiple ge-
netic and nongenetic (environmental1) factors. Among the
most important environmental risk factors are reproductive
factors, such as parity (the number of births) and age at
menarche, but exogenous hormone use, anthropometric fac-
tors, such as body height and body mass index (BMI), and
several other lifestyle factors are also associated with breast
cancer risk [Bakken et al., 2011; Bergstro¨met al., 2001;Clavel-
Chapelon, 2002; Collaborative Group on Hormonal Factors
in Breast Cancer, 1996; Ewertz et al., 1990; Key et al., 2006;
Ursin et al., 1995; van den Brandt et al., 2000]. Neverthe-
less, one of the strongest risk factors for breast cancer is
having a family member with a diagnosis of breast cancer
[Pharoah et al., 1997]. Several high-penetrance genes, such
asBRCA1 andBRCA2, aswell asmoderate penetrance genetic
risk variants have been identified. Disease-causingmutations
inBRCA1 andBRCA2 increasebreast cancer riskup to20-fold
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1Environmental factors include all factors that are not directly measurable from
genomic DNA but could nevertheless be partly genetically determined.
[Mavaddat et al., 2010; Stratton and Rahman, 2008]. How-
ever, due to the low frequency of the high-risk and moderate
risk variants, they account for only about 20% of familial
breast cancer. Genetic association analyses have addition-
ally identified a number of common genetic susceptibility
variants. Recently, the large-scale Collaborative Oncological
Gene-environment Study (COGS) validated 23 of 27 previ-
ously established breast cancer loci and identified 41 new loci
associated with overall breast cancer risk, 4 additional loci
for estrogen receptor negative breast cancer, and 2 loci for
BRCA1 and BRCA2 mutation carriers [Couch et al., 2013;
Garcia-Closas et al., 2013; Gaudet et al., 2013; Michailidou
et al., 2013]. All the common genetic loci, taken together,
have been estimated to explain about 30% of familial risk
[Michailidou et al., 2013]. Gene-gene and gene-environment
(G × E) interactions may explain a further part of the re-
maining familial breast cancer risk [Mavaddat et al., 2010].
Testing for interactions with previously identified common
susceptibility variants for breast cancer has led to very few
consistent results [Campa et al., 2011; Marian et al., 2011;
Milne et al., 2010; Nickels et al., 2013; Prentice et al., 2010,
2009; Rebbeck et al., 2009; Travis et al., 2010].
An agnostic approach to identify G × E interactions using
existing genome-wide association data has been considered
a largely untapped potential means to detect new genetic
variants associated with disease risk [Thomas et al., 2012].
As the standard case-control approach is known to have low
power for detecting multiplicative G × E interactions, al-
ternative methods with greater power have been developed
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Table 1. Description of the environmental risk factors by case-control status from 23 studies in the BCAC
Risk factor Category Cases Controls All
Reference age N 34,475 34,786 69,261
N premenopausal 13,954 14,532 28,486
N postmenopausal 20,521 20,254 40,775
Mean (SD)a 56.2 (11.2) 55.5 (11.5) 55.9 (11.4)
Number of births (parity) Nb 27,174 28,508 55,682
Mean (SD)a 1.9 (1.3) 2.0 (1.3) 1.9 (1.3)
Age at menarche (menarche) Nb 21,942 23,109 45,051
Mean (SD)a 13.1 (1.6) 13.1 (1.6) 13.1 (1.6)
Adult body height (cm, height) Nb 24,016 20,178 44,194
Mean (SD)a 164 (6.6) 165 (6.6) 164 (6.6)
BMI (kg/m2, postmenopausal women, BMI post) Nb 4,423 4,468 8,891
Mean (SD)a 25.2 (4.5) 24.8 (4.2) 25.0 (4.4)
BMI (kg/m2, premenopausal women, BMI pre) Nb 1,759 1,446 3,205
Mean (SD)a 24.7 (5.1) 25.5 (5.6) 25.0 (5.4)
Use of oral contraceptives (years, oral contraceptive duration) Nb 11,017 11,911 22,928
Mean (SD)a 5.3 (7.0) 5.9 (7.1) 5.6 (7.1)
Estrogen-progesterone therapy (years, postm. women,a estrogen-progesterone therapy duration) Nb 3,790 4,057 7,847
Mean (SD)a 1.7 (4.3) 1.2 (3.7) 1.4 (4.0)
Estrogen therapy (years, postm. women,a estrogen therapy duration) Nb 3,876 4,085 7,961
Mean (SD)a 1.3 (4.1) 1.0 (3.5) 1.1 (3.8)
Alcohol consumption (grams per day, alcohol) Nb 3,812 4,055 7,867
Mean (SD)a 7.3 (16.0) 6.8 (11.3) 7.1 (13.8)
Family history of breast cancer (famhist) Nb 20,108 18,522 38,630
Yes (%) 4,213 (21%) 1,606 (9%) 5,819 (15%)
a Women who stopped hormone therapy before diagnosis/interview were assigned 0 years of therapy.
b N is the final sample size for analysis without individuals with unknown values in the variable or any of the adjustment variables.
for testing for G × E interactions in large-scale associa-
tion studies [Mukherjee et al., 2012]. For large-scale scans,
two-step procedures attempt to gain power through enrich-
ment of possible G × E interaction after a first screening step
for marginal genetic association and/or G × E correlation
[Gauderman et al., 2013; Hsu et al., 2012; Murcray et al.,
2011]. Testing jointly for marginal genetic association and
G × E interaction in a two degree of freedom (df) test has
been shown to achieve good power in gene discovery [Dai
et al., 2012; Kraft et al., 2007].
We, therefore, aimed to identify new breast cancer suscep-
tibility loci using about 71,500 single nucleotide polymor-
phisms (SNPs) enriched for association with breast cancer,
by employing different recently proposed methods that ac-
count for G × E interaction in a large pooled dataset from




We analyzed primary data from 21 case-control and 2 co-
hort studies in European populations participating in BCAC
(Supplementary Table S1). These studies fulfilled the criteria
of comprising individuals of European descent and having
at least 200 cases and 200 controls with information on age
and at least one of the environmental risk factors of interest.
All studies were approved by the relevant ethics committees
and informed consent was obtained from all participants.
All studies collected data with standardized questionnaires.
To reconcile differences in study questionnaires, a multistep
harmonization procedure was applied to data submitted by
all studies according to a common data dictionary. All time-
dependent variables were assessed at reference age, whichwas
defined as the age at diagnosis for cases and the age at en-
rolment for controls in cohort studies, and age at diagnosis
for cases and age at interview for controls in case-control
studies [Nickels et al., 2013]. Menopausal status was defined
based on reference age: women aged ≤54 years were con-
sidered as being premenopausal and women aged >54 years
as being postmenopausal [Nickels et al., 2013]. To calculate
adult BMI, we used the variable “usual weight.” For this vari-
able,womenwere asked for their usualweight in adulthoodor
their weight a year ago. Participants were excluded from anal-
ysis if they were male, were prevalent cases at recruitment in
Melbourne Collaborative Cohort Study (MCCS), were not
of European descent, or had a missing value for reference
age, the specific environmental variable of interest, or the re-
lated adjustment variables. The number of women included
in analyses therefore varied according to the environmental
factor being studied (Table 1).
Genetic Information
Genotyping was carried out in BCAC with the collab-
oration of three other consortia as part of the COGS.
Details of initial SNP selection, genotyping, and quality-
control criteria are available in the supplementary ma-
terial of a recent publication [Michailidou et al., 2013].
Briefly, genotyping of 211,155 SNPs proposed by the four
consortia was carried out using an Illumina iSelect geno-
typing array (iCOGS). Of the 70,862 SNPs proposed by
BCAC, 61,240 SNPs had originally been selected from a
meta-analysis of nine genome-wide association studies of
breast cancer risk, which has led to the discovery of 41
new susceptibility loci for breast cancer [Michailidou et al.,
2013]. The remaining SNPs were (i) for fine mapping of
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known susceptibility loci, (ii) in selected candidate genes
or pathways (iii) potentially related to prognosis, or (iii)
associated with cancer-related quantitative traits or other
cancers. After genotyping, standard quality-controlmeasures
were applied to all SNPs and all samples genotyped. SNPs
were excluded from the database if their genotypes were dis-
crepant in more than 2% of the duplicate samples across all
consortia using this array. SNPs were also excluded if their
call rates were below 95% or if their distribution in con-
trols strongly deviated from Hardy–Weinberg Equilibrium
(P < 10–6). Study participants were excluded from all analyses
if the overall call rate was below 95% or if heterozygosity
deviated significantly from that expected in the general pop-
ulation (either lower or higher, P < 10–6). We used genotype
data of 87,658 SNPs nominated by BCAC as well as SNPs
of common interest, for example, because of possible asso-
ciation with breast cancer related traits or other cancer sites,
which remained after application of quality-control criteria.
The present analysis aimed to identify new breast cancer sus-
ceptibility loci by considering G × E interaction, therefore
fine mapping SNPs for the previously identified regions were
excluded from analysis, leading to a final number of 71,527
SNPs. Genotype intensity cluster plots were checked manu-
ally for SNPs in each new region yielding a statistically sig-
nificant G × E interaction using any one of the methods em-
ployed and SNPs were eliminated if the clustering was judged
to be poor. SNP annotations were checked using HaploReg
v2 [Ward and Kellis, 2012], and the UCSC Genome Browser
[Meyer et al., 2013]. Information on linkage disequilibrium
(LD) structure around identified SNPs was obtained using
SNP Annotation and Proxy Search (SNAP) [Johnson et al.,
2008].
Statistical Analysis
Ten established environmental risk factors for breast can-
cer were considered. The specific risk variables were selected
based on the marginal effects for these risk factors derived
frommeta-analyses of the nine population-based studies and
included number of full-term pregnancies, age at menarche,
adult body height, adult BMI (separately for postmenopausal
and premenopausal women), duration of oral contracep-
tive use, duration of menopausal hormone therapy in cur-
rent users (separately for estrogen-progesterone therapy and
estrogen-only therapy), averagedaily alcohol intake, and fam-
ily history of breast cancer in first-degree relatives. All 10 en-
vironmental variables were evaluated as continuous variables
with the exception of family history of breast cancer.
SNPswere assessedusing a log-additivemodel, inwhich the
SNPs are coded according to the number of minor alleles (0–
1–2) and analyzed as continuous variables. All analyses were
adjusted for reference age, study, and six principal compo-
nents (PCs) to account for population stratification, with an
additional PC for the study Leuven Multidisciplinary Breast
Centre (LMBC). The PCs had initially been derived by ana-
lyzing 37,000 uncorrelated SNPs that had been genotyped on
the same array for other consortia [Michailidou et al., 2013].
Further adjustment variables or restrictions were applied ac-
cording to the environmental variables assessed (Supplemen-
tary Table S2).
Four recently proposed methods that exploit G × E inter-
action to detect new disease-associated SNPs were applied.
Three methods were designed to test for G × E interaction:
(i) the hybrid two-step (H2) approach, (ii) a cocktail method
(Cocktail), and (iii) a joint screening (EDG × E) approach
[Gauderman et al., 2013; Hsu et al., 2012; Murcray et al.,
2011]. The fourth method was designed to test jointly for
genetic main effect and G × E interaction: the 2df test [Dai
et al., 2012]. The H2, Cocktail, and EDG × E approaches
are two-step approaches, which combine a testing step with
a screening step and a multiple testing correction module.
All three methods use the same two tests in the screening
step. The first test is a marginal test for genetic association,
where the association of the SNPs with the disease of inter-
est is tested without inclusion of the environmental factor.
The second test in the screening step tests for correlation be-
tween the environmental factor and the SNP, where one is
used as an explanatory variable for the other. This test is per-
formed in combined cases and controls, and takes advantage
of the oversampling of cases as compared with the general
population.
The H2 approach sets certain P-value thresholds for SNPs
to pass the marginal and the correlation screening step
[Murcray et al., 2011]. Only those SNPs that pass at least
one of the screening steps are further tested for G × E inter-
action. For the screening step forH2, the proposed thresholds
of 10–5 for themarginal screening step and 10–3 for the corre-
lation screening were used. G × E interaction is tested using
the likelihood ratio test to compare the logistic regression
models with and without an interaction term, as in standard
case-control analysis. The P-value thresholds for the testing
step are calculated by dividing the desired P-value level by the
number of SNPs that passed the respective screening step. As
two screening steps are performed, a weighting factor of 0.5
is applied to both (giving them equal weight) in order to
maintain the overall significance level. SNPs that pass both
screening steps are assigned the higher P-value.
In the Cocktail approach, the common screening P-value
is assigned the P-value of the correlation screening if this
P-value is below a predefined threshold (in our case 10–3)
[Hsu et al., 2012]. Otherwise, it is assigned the P-value from
the marginal screening test. For the testing step, either stan-
dard case-control analysis or a case-only analysis is applied
depending on the P-values in the screening tests [Hsu et al.,
2012]. If the screening P-value corresponds to the P-value
from the marginal screening, SNPs are tested with case-only
analysis and case-control analysis otherwise. Subsequently,
all SNPs are sorted in ascending order by the screening P-
value. According to the weighted hypothesis testing, j groups
of increasing size are formed by the equation: sizej = 5× 2(j–1).
All SNPs of j groups are assigned identical alpha thresholds
by the formula: aj = 0.05/[5 × 2(2j–1)], which ensures that the
overall desired alpha level of 0.05 is maintained [Ionita-Laza
et al., 2007]. A SNP is considered significant in the Cocktail
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approach if the P-value from the testing step is below the
alpha threshold for the respective group determined in the
screening step.
The EDG × E approach combines the chi-square values
from both screening tests into one value and compares it
with the chi-square distribution at 2 df [Gauderman et al.,
2013]. Resulting P-values are sorted in ascending order and
alpha thresholds for j groups are calculated according to the
weighted hypothesis testing approach. In the testing step,
the EDG × E approach uses case-control analysis and the
resulting P-values are compared to the thresholds calculated
based on the screening step.
The 2df test jointly tests marginal association and G × E
interaction [Kraft et al., 2007]. We employed the newly pro-
posed procedure to combine the two independent tests for
the marginal genetic association and for the G × E inter-
action, exploiting the independence between the two tests
[Dai et al., 2012]. This is a chi-squared test applied to the
sum of the two squared z scores or log P-values. To correct
for multiple testing, Bonferroni correction was applied lead-
ing to a P-value threshold of about 7 × 10–7 in the present
analysis. Dai et al. offered three different options to test for
G× E interaction, of which the standard case-control logistic
regression was chosen to avoid biased results due to violation
of the G × E independence assumption in the population
[Dai et al., 2012].
For comparison, standard case-control logistic regression
(CC) for G × E interaction with the Bonferroni-corrected
P-value threshold of 7 × 10–7 was also applied. To assess
study heterogeneity, we estimated odds ratios (OR) for the
per-allele genetic main effect and G × E interaction for each
individual study, adjusting for age, and assessed P-values for
heterogeneity using aQ-test. Subjects with missing data for a
particular SNP or environmental factor were excluded from
the respective analysis. We also calculated stratum-specific
per-allele ORs for each SNP tested statistically significant
using any one of the methods employed. Data preparation
and statistical analyses were performed with SAS software
(release 9.2) and the R Language and Environment for Sta-
tistical Computing, version 2.15.0.
Results
The mean age at recruitment of the study participants was
56 years (Table 1). The sample size and number of studies
included for the analyses of the 10 different environmental
variables varied between 3,205women from4 studies for BMI
among premenopausal women and 55,682 women from 22
studies for the number of full-term pregnancies. The exact
numbers by study are shown in Supplementary Table S3.
Overall, three SNPs showing a statistically significant as-
sociation were detected in the analysis of G × E interaction
between 10 environmental variables and 71,527 SNPs. Not
all were detected by all four methods applied and none was
detected using the standard CC approach. All three SNPs
were found with the 2df test (Table 2). The latter two of these
SNPs were also found to show statistically significant interac-
tion using the other three approaches (Supplementary Tables
S4a–c). One SNP is located on chromosome 6 and the other
two SNPs are located on chromosome 21q22.12. The latter
two SNPs lie in a distance of about 4,000 base pairs, which
makes recombination unlikely [Li and Freudenberg, 2009],
and are in perfect LD (r2 = 1.0) [Hapmap, 2013]. The SNPs,
which were all found to be statistically significantly associ-
ated using the 2df test, have not been identified previously
as being associated with breast cancer risk and are not in LD
with known susceptibility loci.
The two associated SNPs on chromosome 21q22.12
(rs10483028 and rs2242714) were identified by analyzing
interaction with adult BMI in a sample of 8,891 post-
menopausal women from seven studies. Considering theG×
E interaction effect (OR = 0.84) was essential for the identifi-
cation of the two SNPs. The SNP rs10483028 on chromosome
21 showed a decreased effect with increasing BMI, the per-
alleleORs being 1.26 (95%CI 1.15–1.38) inwomenwithBMI
<25 kg/m2, 1.10 (95% CI 0.96–1.26) in women with BMI be-
tween 25 kg/m2 and 30 kg/m2, and 0.89 (95% CI 0.72–1.11)
in women with BMI >30 kg/m2 (Fig. 1).
SNP rs12197388 on chromosome 6 was identified in inter-
action analyses with age at menarche and with parity. This
SNP did not show a clear G × E interaction (OR = 1.09) with
either risk factor but passed the threshold of the 2df test (7 ×
10–7) due to its highly significant marginal association (P < 6
× 10–8).
There was little or no evidence for heterogeneity by study
in the G × E interaction ORs for the three identified SNPs.
This was also true for the marginal associations of the SNPs
with breast cancer risk (Supplementary Table S5 and Sup-
plementary Figure S1 [panel A1–A4]). None of the three
identified SNPs had been selected for COGS Illumina iSelect
genotyping array (iCOGS) with respect to the environmen-
tal factors studied and none was found to be substantially
correlated with parity/age at menarche and adult BMI in
Table 2. Significantly associated SNPs with P < 7 × 10−7 in the analysis of multiplicative interaction between 71,527 SNPs and 10
environmental risk factors for breast cancer, using the 2df test
SNP Chromosome Region Position build 36 Environmental variable P-value marginal OR marginal P-value interaction OR interaction P-value 2df test
rs12197388 6 ARID1B 161630341 Parity 5.69 × 10–8 1.09 0.37 1.01 2.68 × 10–7
Menarche 5.24 × 10–8 1.09 0.52 0.99 2.99 × 10–7
rs10483028a 21 21q22.12 35595443 BMI post 1.70 × 10–5 1.17 3.19 × 10–5 0.84 1.68 × 10–8
rs2242714a 21 21q22.12 35599557 BMI post 2.47 × 10–5 1.16 4.12 × 10–5 0.84 3.07 × 10–8
a These two SNPs were also identified to show statistically significant multiplicative interaction with BMI using the H2, Cocktail, and EDG × E approaches (see
Supplementary Tables S4a–c).
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Figure 1. Effect of rs10483028 on breast cancer risk by strata of adult
BMI in 8,891 postmenopausal women from BCAC.
postmenopausal women, respectively (Supplementary Table
S6).
Discussion
Toourknowledge, this is thefirst large-scale agnostic search
for G × E interaction to identify new susceptibility loci for
breast cancer. To gain power, three recently developed two-
step approaches for testing for G × E interaction as well as
a joint test for marginal association and G × E interaction
were used.We identified three SNPs representing two genetic
loci associated with breast cancer risk.
The two SNPs rs10483028 and rs2242714 on chromosome
21q22.12 showing strongG×E interaction effects are located
outside known genes. Nevertheless, as shown for the region
8q24, these regions might contain enhancer elements, which
may affect the expression of genes in the vicinity [Ahmadiyeh
et al., 2010]. There are several SNPs in strong LD (r2 > 0.8)
with rs10483028 and rs2242714 (Supplementary Figure S3).
However, none of them is located in a known regulatory ele-
ment (Supplementary Figure S4). TheRUNX1 gene is located
approximately 300 kb upstream of the two SNPs and has a
tumor suppressor role reflected by many somatic mutations
in breast tumors. The tumor suppressor activity of RUNX1 is
considered to be mediated in part by antagonism of estrogen
signaling [Chimge and Frenkel, 2013]. Recurrent mutations
in the CBFB transcription factor gene and deletions of its
partner RUNX1 also indicated inactivation of this transcrip-
tion factor complex in breast cancer [Banerji et al., 2012].
The identified SNP rs12197388 is located on chromosome
6 in an intronic region of ARID1B, which belongs to the
SWI/SNF chromatin remodeling complex family. SWI/SNF
complexes have the ability to enhance or suppress gene tran-
scription by mobilizing nucleosomes [Weissman and Knud-
sen, 2009]. ARID1B has recently been implicated in breast
cancer development through the identification of driver mu-
tations, which confer clonal selective advantage on cancer
cells [Stephens et al., 2012]. This gene has been shown to
act as a tumor suppressor in pancreatic cancer cell lines
[Khursheed et al., 2013].Mutations in the SWI/SNF complex
have also been associated with certain types of syndromes,
among those the ARID1B-related intellectual disability syn-
drome [Kosho et al., 2013] as well as with early treatment
failure and decreased survival in children with neuroblas-
toma [Sausen et al., 2013]. Whether rs12197388 potentially
influences ARID1B function is unclear, as it does not seem to
be associated with regulatory elements, and there are no fur-
ther SNPs in at least moderate LD (r2 > 0.6) with rs12197388
based on data from the 1000 Genomes Project (Supplemen-
tary Figure S2).
Our results indicate that accounting for G × E interaction
using two-step/hybrid methods can lead to the identification
of new susceptibility loci. All three methods that test only for
G × E interaction identified the two SNPs on chromosome
21 because of a strong interaction between the SNPs and BMI
in postmenopausal women but not the SNP rs12197388 on
chromosome 6 because of the absence of G × E interaction.
This suggests comparable power of these methods based on
empirical evidence, which was also demonstrated by simu-
lation studies [Mukherjee et al., 2012]. The consistency of
the results between methods provides some support for the
robustness of the finding. The SNP rs12197388, on the other
hand, was identified through its marginal effect on breast
cancer risk. The association between rs12197388 and breast
cancer risk was weaker if all subjects of European descent
from BCAC were included, irrespective of the availability
of information on the respective environmental risk factors
(OR=1.05,P=7.2×10–5). Because the genetic associationwas
not genome-wide statistically significant, rs12197388was not
identified as susceptibility locus for breast cancer in the recent
publication [Michailidou et al., 2013]. Restricted to studies
that collected information on epidemiologic risks, our find-
ing could be due to chance or through introducing a selection
bias that we are currently not able to explain. However, both
themarginal associationwithbreast cancer riskof rs12197388
and the estimates for G × E with number of births and age
at menarche were not heterogeneous between studies in the
current analysis (Supplementary Figure S1). For the other
two SNPs, rs10483028 and rs2242714, which showed statis-
tical interaction with adult BMI in postmenopausal women,
the association with breast cancer risk was weaker but still
apparent when analyzed in all postmenopausal subjects of
European descent in BCAC (OR = 1.06, P-value = 0.001).
Large sample sizes, comprisingmore than 20,000 cases and
controls, were available for the present interaction analyses
with number of births, age at menarche, and adult body
height. However, sample size was moderate for analyses with
most of the other risk factors, such as BMI and menopausal
hormone therapy. Multiplicative interactions identified to
date between environmental risk factors and common breast
cancer susceptibility alleles have been weak or at most mod-
erate [Nickels et al., 2013]. An at least fourfold larger sample
size has been shown to be necessary for the identification of
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G × E effects of the same order of magnitude as compared to
marginal effects [Smith and Day, 1984]. Therefore, statistical
power to detect an interaction with the other risk factors was
still limited [Hein et al., 2008].
It is likely that further susceptibility loci for breast cancer
that predominantly act through G × E interactions can be
identified in the human genome. Of the set of SNPs in the
present analysis, approximately 61,240were selected based on
evidence of association with breast cancer or specifically es-
trogen receptor negative disease [Garcia-Closas et al., 2013;
Michailidou et al., 2013]. A detectable genetic effect, how-
ever, is not a prerequisite for the identification of G × E in-
teraction effects. Thus, further SNPs with G × E interaction
could be identifiedwhen expanding the set of geneticmarkers
considered.
As the present analyses were based on preselected SNPs,
the parameters used for the methods, which are designed
for genome-wide G × E detection, might not have been
optimal in this setting. The H2 and the Cocktail approach
require thresholds for the screening step P-values, which can
be arbitrary. For the H2 approach, we used the thresholds
for the screening steps, which were proposed by the authors
and found to be optimal in most of their simulation con-
figurations [Murcray et al., 2011]. Similarly, for the Cocktail
approach we used the threshold that had been originally pro-
posed for the Cocktail I approach [Hsu et al., 2012].
Allmethods employed correct inherently formultiple com-
parisons introduced by testing large numbers of SNPs, but
the number of environmental variables tested was not taken
into account. It could be argued that all thresholds should
be reduced by one decimal power to correct for multiple
testing of environmental factors. However, all 10 environ-
mental variables in our analysis are known breast cancer risk
factors. Both SNPs on chromosome 21 would remain signifi-
cant at the 5% level even if the P-value threshold was reduced
by one decimal power to 7 × 10–8. This would not be the
case for rs12197388. Although four different methods were
used, correction ofmultiple testing due to the use of different
methods did not seem appropriate because all the methods
for assessing G × E interaction are highly correlated.
Several studies that contributed to the present analyses
were nonpopulation-based. However, selection bias is not
expected to influence estimates of G× E interactions inmost
circumstances [Morimoto et al., 2003]. We did not observe
pronounced differences between results from population-
based and nonpopulation-based studies in G× E interaction
analyses (Supplementary Figure S1). In a previous publica-
tion on G × E interactions with known breast cancer SNPs,
we also did not observe between-study heterogeneity in inter-
action ORs. In sensitivity analyses, G × E estimates were not
found to change substantially after restriction to population-
based studies only [Nickels et al., 2013]. Differential mis-
classification would rather have led to an underestimation of
interaction effects [Garcia-Closas et al., 1998]. In BCAC, risk
factor information is harmonized thoroughly in a standard-
ized fashion. For cases in case-control and cohort studies,
the reference time was always time at diagnosis. For controls,
reference time was time at interview and therefore at base-
line recruitment for cohort studies. Misclassification of the
menopausal status by using an age surrogate was therefore
unproblematic. But specifically for risk factors that are likely
to change over time (e.g., smoking behavior andmenopausal
hormone therapy use), different referent times for assessment
could lead to heterogeneity of results derived from cohort
vs. case-control studies. As shown in Supplementary Figure
S1 (panel A1, A2, B1, B2), we did not observe heterogene-
ity between case-control and cohort studies. Therefore, the
differing reference times did not bias our results to a great
extent.
Thepresent analyseswere restricted to subjects ofEuropean
ancestry and adjusted for study to reduce bias due to popu-
lation stratification. The present results were consistent with
previous results on marginal SNP associations from BCAC
[Michailidou et al., 2013]. Most of the previously identified
breast cancer susceptibility alleles were again detected by ap-
plication of the 2df test, which also considers the marginal
genetic association.
To conclude, the identification of the new breast cancer
associated loci supports the hypothesis that new risk loci can
be identified by methods that account for G × E interac-
tion in the association analysis. In addition to GWAS for
genetic main effects, this approach may facilitate identifying
a proportion of the susceptibility loci contributing to poly-
genic susceptibility to breast cancer, where association differs
according to the presence or absence of a particular envi-
ronmental factor, or is restricted to those with the environ-
mental factor. Replication of the susceptibility loci identified
through G × E interaction will however require large sample
sizes with environmental risk factor data to achieve adequate
power, which might not be trivial to recruit.
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